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Background: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that
lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing
impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity
can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech
and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood
cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between
childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been
performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However,
results were inconsistent and most studies were underpowered and/or lacked replication.
Objective: We describe the design of the PanCareLIFE consortium’s work packages that address the genetic susceptibility of
platinum-induced ototoxicity.
Methods: As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic
susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a
candidate gene approach and a genome-wide association screening.
Results: This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer,
resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group
of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided,
for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer
using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct
ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication
cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses
and the first results are expected by the end of 2019 or the beginning of 2020. 
Conclusions: Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk
prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the
development of prevention strategies.
International Registered Report Identifier (IRRID): DERR1-10.2196/11868
(JMIR Res Protoc 2019;8(3):e11868)   doi:10.2196/11868
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Introduction
Survival outcomes after childhood cancer have improved
considerably over the last decades, now reaching approximately
80%. This marked increase is a result of advanced diagnostic
and treatment procedures, improved stratification options, and
optimized supportive care [1]. Nevertheless, more than 25% of
all childhood cancer survivors (CCS) are affected with severe
or life-threatening long-term side effects of treatment (eg, heart
failure, secondary malignant neoplasms, and cognitive
dysfunction), and approximately 75% of all CCS experience at
least one long-term side effect [2,3]. Ototoxicity is a side effect
of childhood cancer treatment and is defined by damage to the
cochlea resulting in hearing loss, tinnitus, and/or vertigo [4].
Hearing loss is frequently encountered in childhood cancer
patients and survivors treated with platinum derivatives such
as cisplatin and carboplatin [5-9]. Studies have shown that 45%
to 60% of CCS treated with cisplatin develop irreversible
hearing loss and almost half of them may require hearing aids
[10,11]. Platinum-induced hearing loss usually starts in the high
frequencies but can eventually affect the lower frequencies,
including speech frequencies [12].
Even though hearing loss is not a life-threatening disorder, it is
a serious adverse effect of treatment, especially in children at
ages before and during language acquisition. It can cause
distress, anxiety, and depression leading to problems with speech
development, neurocognitive functioning, school performance,
and social life [6,9,12-14]. Hence, hearing loss can have a large
negative and lifelong impact on quality of life [15]. Currently,
novel therapeutics such as sodium thiosulfate have proven to
be otoprotective, yet they cannot be applied in clinical practice
since these novel therapeutics can reduce the efficacy of
anticancer treatment [16].
Apart from platinum compounds, several other risk factors for
hearing loss during and after childhood cancer therapy have
been identified. These include a high platinum dose, renal
dysfunction, young age at diagnosis, concomitant use of other
potentially ototoxic drugs, and cranial irradiation. However, in
total these factors only partially explain the interindividual
variability in ototoxic responses to platinum [17]. This suggests
that genetic susceptibility may contribute to the occurrence of
hearing loss in CCS. Although several genetic association
studies have been performed so far, their results are uncertain
due to study design, selection of particular candidate genes,
failure of independent replications, and/or the small sample size,
which limits statistical power. In addition, some studies were
heterogeneous with respect to ethnicity and/or the nongenetic
risk profile, particularly the inclusion of cranial irradiated cases
and the types of platinum compounds [6,18,19]. All but one of
the previous studies in pediatric cancer survivors focused on
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genetic associations within prespecified genes of interest (ie,
candidate gene approach), yet it is unclear whether previous
studies indeed have considered the most relevant candidate
genes.
Prerequisites for a satisfactory approach to identification of
genetic determinants of platinum-induced hearing loss would
be adequate numbers of research subjects and well-documented
clinical and treatment data. The multinational PanCareLIFE
(PCL) study provides a unique opportunity to investigate
preexisting and novel genetic markers for treatment-related
hearing loss in CCS [20]. PCL is funded by the European
Union’s Seventh Framework Programme from 2013-2018 and
originated from the PanCare network [21]. Investigators from
10 European countries collected data from over 12,000 CCS in
order to investigate the determinants of long-term health in this
population. PCL addresses three main outcomes: ototoxicity,
fertility impairment, and quality of life.
This study is part of the PCL project and addresses the genetic
susceptibility of platinum-induced hearing loss. Specifically,
the aims were to identify clinical and genetic risk markers in a
large cohort of CCS and identify additional genetic risk markers
of hearing loss by genome-wide association screening (GWAS)
in a carefully characterized subgroup.
Methods
In total, 8 work packages (WPs) are included in the
PanCareLIFE study, of which 5 are scientific WPs. In this study,
WP5 and WP4b will be addressed.
Study Population and Inclusion Criteria
WP5 aimed to identify clinical and genetic risk markers in a
large cohort of CCS. For eligibility in the PCL WP5 genetic
study, the following inclusion criteria were applied: (1) patients
were younger than age 18 years at cancer diagnosis; (2) patients
had been treated for cancer with cisplatin, carboplatin, or both;
(3) patients were off therapy and had at least one pure tone
audiometric evaluation available after the end of chemotherapy;
and (4) patients had provided biomaterial (saliva or blood) for
DNA extraction (Figure 1). Subjects were excluded from the
study if they had permanent hearing loss identified before the
start of cancer therapy.
WP4b used a subset of research subjects from WP5 and aimed
to identify additional genetic risk markers of hearing loss by
GWAS with better control of nongenetic risk factors. An
additional set of inclusion criteria was imposed to reduce
potentially confounding factors and focus on the influence of
cisplatin. These were (1) cancer treatment included upfront
cisplatin, either cisplatin as the single platinum drug throughout
the entire course of treatment or change from cisplatin to
carboplatin during treatment, and (2) no radiotherapy
administration to the brain or inner ear (Figure 1). Research
subjects whose initial treatment included carboplatin were
excluded.
Ethics Approval and Consent to Participate
The PanCareLIFE study has been approved by the local ethics
committees: Kantonale Ethikkommission Bern, 362/2015;
Comitate Etico Regionale, 507REG2014; Ethical Committee
University Hospital Brno, June 11, 2016; Ethics Committee
Fakultni Nemocnice v Motole, Prague; De Videnskabsetiske
Komiteer Region Hovedstaden, H-1-2014-125;
Ethikkommission Medizinische Universität Graz, 27-015 ex
14/15; Ethikkommission der Universität Ulm, 160/17;
Ethikkommission der Universität zu Lübeck, 14/181;
Ethik-Kommission der Ärztekammer Westfalen-Lippe und der
Westfälischen Wilhelms-Universität Münster, 2014-619;
Medische Ethische Toetsings Commissie Erasmus MC; Medisch
Ethische Toetsingscommissie, 2015_202. Informed consent was
obtained from the patient or their the legal representatives.
Data Collection, Storage, and Anonymization
CCS were recruited through an institutional network from
several countries in Europe. The participating institutions are
referred to as data providers. Each data provider collected
retrospective demographic, diagnostic, treatment, and
audiometric data from their medical record files and registries.
Diagnostic data included the International Classification of
Disease –coded diagnosis and date of diagnosis (for each tumor).
Treatment-related data included information on platinum
treatment (eg, platinum compound, dose per cycle, cumulative
dose, date of start and stop treatment, and infusion duration)
and potentially ototoxic comedication (eg, amikacin,
gentamycin, tobramycin, furosemide, vincristine, vancomycin).
The data were stripped of all identifiers and assigned a unique
PCL-ID number, rendering the data pseudonymous for the
investigators of this study. Data providers sent their data to the
PCL data center in Mainz (German Childhood Cancer Registry,
University Medical Center Mainz, Germany), which also
collected and archived the genetic, clinical, and audiological
data from the lab and the audiometry center.
Outcome
The main outcome of this study was hearing function following
platinum treatment in pediatric cancer survivors. Diagnosis of
hearing loss was based on pure tone audiometry performed at
frequencies of 250, 500, 1000, 2000, 4000, 6000, and 8000 Hz
[22]. Data providers sent the pseudonymized original
audiograms to the audiometry center (Department of Phoniatry
and Pediatric Audiology, University Hospital Muenster,
Germany) for standardized review. The audiogram assessors
were blinded to patient characteristics including their treatment,
such as platinum compound, platinum dose, or cranial
irradiation. The assessors graded the severity of hearing loss
using the Muenster criteria [23,24]. The Muenster criteria
considers minimal hearing loss (Muenster grade 1: >10 to ≤20
dB) and allows the detection of early post-cisplatin hearing loss.
Clinically relevant hearing loss was defined as Muenster grade
≥2b [24]. The International Society of Pediatric Oncology
(SIOP) Boston criteria [25,26] was used as an independent,
secondary grading. Clinically relevant hearing loss was defined
as SIOP grade ≥2 (Table 1).
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Figure 1. Description of WP4b and WP5 study cohorts.
Table 1. Applied ototoxicity criteria.
SIOPa Boston criteriaMuenster criteriaGrade
≤20 dB HL at all frequencies≤10 dB HLb at all frequencies0
>20 dB HL above 4 kHz>10 to ≤20 dB HL at one or more frequencies or tinnitus1
>20 dB HL at 4 kHz and above>20 dB HL at 4 kHz and above2
2a: >20 to ≤40 dB
2b: >40 to ≤60 dB
2c: >60 dB
>20 dB HL at 2 kHz and above>20 dB HL at <4 kHz3
3a: >20 to ≤40 dB
3b: >40 to ≤60 dB
3c: >60 dB
>40 dB HL at 2 kHz and above≥80 dB at <4 kHz4
aSIOP: International Society of Pediatric Oncology.
bHL: hearing loss.
DNA Collection and Genotyping
Detailed methods for DNA collection and genotyping are
described elsewhere [27]. For the first aim of the genotype study,
a candidate gene approach was applied to validate 10 previously
identified single nucleotide polymorphisms (SNPs) associated
with hearing loss in childhood cancer patients and survivors
[19,28-40]: ACYP2, LRP2, NFE2L2, OTOS, TPMT, SOD2,
SLC22A2, GSTP1, ABCC3, and SLC16A5 [30,32,35,38,40-43].
In WP4b, array-based genotyping data was used. Thereafter,
these data were merged with data from TaqMan PCR generated
in WP5. Next, novel SNPs that were independently associated
with treatment-related hearing loss in childhood cancer patients
were explored within WP4b by GWAS. For maximum
standardization, array genotyping in the PCL consortium was
conducted by one partner (genetic laboratory of the Department
of Internal Medicine in the Erasmus Medical Center, Rotterdam,
the Netherlands) [44]. The Infinium Global Screening Array
(Illumina, Inc), which contains >770,000 SNPs, was used [45].
Quality Control and Imputations
A stringent quality control protocol was applied where multiple
filters were used to ensure the quality of the genetic data prior
to either imputations or analysis. The quality control procedure
is described elsewhere [27]. To remove poorly genotyped SNPs
and individuals from the data, a call rate of 97.5% was applied.
In addition, a Hardy-Weinberg equilibrium test (P<1*10–7) was
assessed to identify potential genotyping errors. Samples with
gender mismatches, familial relationships, and extreme
heterozygosity were removed to ensure sample quality. After
the quality control, principal components were calculated in
order to adjust for population heterogeneity and technical
confounders in all subsequent analyses [46]. Imputations were
performed using the Michigan Imputation Server with default
settings [47]. The reference panel chosen for imputations was
the Haplotype Reference Consortium (HRC r1.1) [48]. This
panel has also been used in large-scale population-based studies
such as the Rotterdam Study [49] and Generation R [50].
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Statistical Power
To estimate the number of cases required for the GWAS
analyses, a sample size calculation was performed. Assuming
a risk allele frequency of 0.2, a case to control ratio of 1:1, and
a P value threshold of P<5*10–8 for the GWAS analysis, a
cohort of 574 patients was considered sufficient to detect an
odds ratio of at least 2.8 with a statistical power of 80% in the
design of the study.
Genetic Susceptibility Analysis
For both candidate gene and GWAS analyses, genetic profiles
from children who were treated with cisplatin and have hearing
impairment were compared to those of children treated with
cisplatin who did not develop hearing impairment. Relationships
of categorical data were compared using the chi-square and
Fisher exact tests. Comparison of distribution between groups
with continuous data was tested with the Mann-Whitney and
Kruskal-Wallis tests. Standard logistic regression models
adjusting for age at diagnosis, gender, total cumulative cisplatin
dose, and principal components were employed to calculate
odds ratios with 95% confidence intervals in order to assess the
risk of hearing loss. Principal component analysis, a common
tool that has been widely used for the combined analysis of
correlated phenotypes in genetic linkage and association studies,
was used to correct for population stratification by modeling
ancestry differences between cases and controls. Bonferroni
correction was used in the candidate gene analysis to adjust for
multiple testing. In the GWAS, a suggestive significance
threshold of P<1*10–6 was used to identify relevant SNPs that
could be important but did not reach genome-wide significance
(P<5*10–8). All statistical analyses were performed by
investigators of WP4b and WP5 in close collaboration with the
Biostatistical Support Group of UMC Mainz and Ulm.
For both the WP4b candidate gene approach and WP4b GWAS,
replication analysis is planned within an independent Canadian
cohort from the Canadian Pharmacogenomics Network for Drug
Safety (CPNDS).
Results
Study participants were recruited through a network of 14
institutions from 7 countries: Switzerland, Italy, Czech Republic,
Denmark, Germany, Austria, and the Netherlands. The data
providers and number of patients per data provider are shown
in Table 2; data providers and locations are depicted on a map
in Figure 2. WP5 ultimately enrolled a total of 1124 patients.
Compared to WP5, WP4b investigated a more restricted study
population of 598 patients. Germline DNA, extracted from
EDTA blood or saliva samples, was used for genotype studies.
To reduce patient discomfort and boost study enrollment, saliva
was allowed as an alternative to blood. In total, the data
providers collected a similar number of blood and saliva
samples. Biosamples were stored and processed at the University
Medical Center Ulm, Germany, and at the Erasmus Medical
Center Rotterdam, the Netherlands, until analysis. Blood samples
were stored at –20°C or lower; saliva samples were stored at
room temperature. Germline DNA was extracted using the
salting-out method and served as a template for TaqMan
polymerase chain reaction (PCR; WP5) and array-based
genotyping (WP4b).
Patient recruitment started in January 2015 and final inclusion
was October 2017. We are currently performing the analyses
and the first results are expected by the end of 2019 or the
beginning of 2020.
Table 2. Data providers included in the genetics study.
Patients enrolled in WP4bbPatients enrolled in WP5aCountryData provider
73153SwitzerlandUniversity of Bern, Bern
88ItalyIstituto Giannina Gaslini, Genova
54173Czech RepublicUniversity Hospital Brno, Brno
4186Czech RepublicMotol Teaching Hospital Prague, Prague
3594DenmarkKraeftens Bekaempelse, Copenhagen
107124GermanyOsteosarcoma clinical trial
111297GermanyUniversity Hospital Muenster, Muenster
3436GermanyEuramos clinical trial
1230GermanyUniversity Lübeck, Lübeck
1029AustriaUniversity Graz, Graz
2217The NetherlandsAcademical Medical Center Amsterdam, Amsterdam
3232The NetherlandsErasmus Medical Center, Rotterdam
1818The NetherlandsUniversity Medical Center Groningen, Groningen
2727The NetherlandsPrincess Máxima Center for Pediatric Oncology, Utrecht
aWP5: work package 5.
bWP4b: work package 4b.
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Figure 2. Data providers participating in WP4b and WP5 of PanCareLIFE: University of Bern, Instituto Giannina Gaslini, University Hospital Brno,
Motol Teaching Hospital Prague, Kraeftens Bekaempelse, University Graz, Osteosarcoma clinical trial, University Hospital Muenster, Euramos clinical
trial, University Lübeck, Academical Medical Center Amsterdam, Erasmus Medical Center Rotterdam, University Medical Center Groningen and
Princess Máxima Center for Pediatric Oncology Utrecht. PanCareLIFE study management: Boyne Research Institute Drogheda and German Childhood
Cancer Registry Mainz.
Discussion
Principal Findings
This paper describes the design of the PCL ototoxicity genetics
study aiming to identify clinical and genetic risk markers in a
large and heterogeneous cohort of CCS and identify additional
genetic risk markers of hearing loss by GWAS with better
control of nongenetic risk factors in a more homogenous
subcohort of CCS. Data were collected from 1124 CCS from 7
different European countries. Some of the previously identified
genetic variants for hearing loss were validated by a candidate
gene approach. In addition, the first international GWAS of
cisplatin-induced hearing loss sets out to identify novel allelic
variants in the largest European cohort assembled for such a
genome-wide pharmacogenetics association study so far.
For this study, a subcohort was recruited consisting of patients
who were treated with cisplatin and did not receive cranial
irradiation, a well-known independent risk factor for
sensorineural hearing loss. From 14% to 27% of children who
received radiotherapy without ototoxic chemotherapy suffered
from high-frequency hearing loss [51,52]. This risk of hearing
loss increases in patients who require platinum-based
chemotherapy combined with radiation. Whether the same
genetic markers are associated with platinum- and
radiation-induced hearing loss is unknown. To limit
contamination by the presence of confounding factors such as
cranial irradiation, a more homogenous subcohort of patients
was selected for WP4b.
Appropriately sized cohorts are required to identify genetic
determinants of platinum-induced hearing loss. The many
associations that are tested in a GWAS require a very low
significance threshold to prevent an inflated genome-wide type
I error. This reduces the probability of identifying SNPs with
small effect size, unless sample sizes are large enough to achieve
sufficient power to identify such SNPs. The large combined
cohort within the PCL consortium is expected to provide
adequate statistical power.
Many classification systems of drug-induced hearing loss have
been developed—Brock grading system [53], American
Speech-Language-Hearing Association (ASHA) criteria [54],
JMIR Res Protoc 2019 | vol. 8 | iss. 3 | e11868 | p.6http://www.researchprotocols.org/2019/3/e11868/
(page number not for citation purposes)
Clemens et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Chang classification [55], Muenster classification [24], and the
SIOP Boston Ototoxicity Grading Scale [26]—yet an
international standard for ototoxicity reporting is still lacking.
Choice of the classification system and definitions of hearing
loss may have an impact on the frequency of occurrence in
childhood cancer survivors [56], as shown in a recent study that
investigated the influence of several classification methods in
a large prospective cohort of platinum-treated children and
adolescents. Estimates of the overall occurrence of hearing loss
(40% to 56%) and severe hearing loss (7% to 22%) cover a wide
range [57]. Compared to other methods, Muenster grade 1 is
considered a strong predictor for the need of hearing support in
CCS, with reported sensitivity and specificity levels of 67%
and 87%, respectively [58]. In addition, the SIOP Boston scale
might be superior to determine hearing loss compared to the
ASHA, Brock, and Common Terminology Criteria for Adverse
Events (CTCAE) methods, based on the high number of
evaluable assessments, sensitivity, and earliest time to detect
hearing loss [57]. In order to strengthen our study, both the
Muenster classification and SIOP Boston scale were used for a
valid interpretation of the severity of platinum-induced hearing
loss in this cohort.
The availability of a large European set of clinical, audiometric,
and genetic data provides the PCL consortium excellent
opportunities for further collaboration, including replication
studies in independent transatlantic cohorts or meta-analyses.
In order to validate findings from the initial discovery cohort,
it is standard practice to include an independent replication
cohort. A collaboration with the CPNDS for replication of results
of this study has been initiated. The patients enrolled in our
replication cohort were recruited from 11 hospitals and health
care centers in Canada. Hearing loss in the CPNDS cohort was
originally graded according to the CTCAE [29]. Applying a
standardized definition for hearing loss facilitates a combined
analysis of the CPNDS and PCL data. For that purpose, end
point harmonization was pursued by reevaluating all audiograms
(EC) of the CPNDS cohort according to Muenster and SIOP
criteria. Additional replication cohorts could be needed for
future international collaborations.
Limitations
The PanCareLIFE ototoxicity studies have some limitations.
As a result of missing or unclassifiable audiograms, some
patients cannot be included due to a missing phenotype. Because
many of the patients with missing audiograms might have good
hearing function, they might therefore no longer be followed
up for audiometric testing, As a consequence, the risk of
ototoxicity based on the results of this study might be an
overestimation of the true risk. Currently, the International Late
Effects of Childhood Cancer Guideline Harmonization Group
is developing recommendations for audiological monitoring in
CCS. The guideline unifies existing recommendations and
provides optimum follow-up practices, which is important for
consensus on the frequency and timing of audiological
evaluations after childhood cancer [59].
Conclusions
In summary, our paper described the design of a genetic
susceptibility study that addresses an important late effect of
cancer therapy (ie, platinum-induced hearing loss in survivors
of cancer diagnosed and treated during childhood). Identification
of genetic risk factors may assist in the development of more
accurate prediction models that can be incorporated in future
clinical trials of platinum-based therapies for cancer. Increased
knowledge of nongenetic and genetic risk factors of
cisplatin-induced hearing loss may contribute to the development
of preventive methods to improve quality of life in CCS.
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